---
title: "Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch"
date: "2025-02-07 21:53:05"
summary: "passorn santiwiriyanon/E+ via Getty Images  Coya Therapeutics (NASDAQ:COYA) suffered a major setback back in 2024 when it released data from its phase 2 study using Low-Dose [LD] IL-2 COYA-301 for the treatment of patients with Alzheimer's Disease [AD]. This caused the"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170277408/image_2170277408.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Hydroponic vegetables salad farm](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170277408/image_2170277408.jpg?io=getty-c-w750) 



passorn santiwiriyanon/E+ via Getty Images





**Coya Therapeutics** (NASDAQ:[COYA](https://seekingalpha.com/symbol/COYA "Coya Therapeutics, Inc.")) suffered a major setback back in 2024 when it released data from its phase 2 study using Low-Dose [LD] IL-2 COYA-301 for the treatment of patients with Alzheimer's Disease [AD]. This caused the

[seekalpha_articles](https://seekingalpha.com/article/4756164-coya-a-few-catalysts-on-the-way-for-coya-302)
